Merck & Co., Inc.

NYSE:MRK

Drug Manufacturers - General

Healthcare
$137.78 -1.14%

-$1.32 today

Market cap
$339.66B
Beta
0.22
P/E (TTM)
31.6
EPS (TTM)
$3.61
Dividend yield
2.94%
52W Low $76.66High $125.14

Volume 9.69M

Average 11.85M

MRK Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Merck & Co., Inc.NYSE: MRK

Operating Expenses · Q2 FY2026 · quarter ended Jun 2026

Operating expenses growth accelerates

Q2 FY2026 operating expenses of $12.9B rose 130.5% year over year, ahead of the +46.3% change in trailing-twelve-month operating expenses. Sequentially, it fell 15.3% from the prior quarter. Over 3 fiscal years it compounded at -0.5% a year.

Context

  • Operating expenses amounted to 35.8% of revenue in FY2025, down 9.0 pp from a year earlier.
  • Operating expenses increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +130.5% holds above the trailing-twelve-month pace of +46.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$12.9B-15.3% QoQ
Last fiscal yearDec 2025
$23.25B-19.2% YoY
LTMJun 2026
$38.99B+46.3% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+130.5%——
1 year-19.2%——
3-year CAGR-0.5%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
23.25B USD
Year-over-year change
-19.2%
4-year CAGR
+1.5%

Operating Expenses vs competitors

How MRK compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +46.3% is the 2nd highest of 10, against a peer median of +5.1%.
  • Operating expenses amounts to 58.7% of revenue for MRK, versus a peer median of 43.9%.
MRK Competitors
Operating Expenses for MRK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JNJJohnson & JohnsonLTM Sep 2026$42.83B USD+10.7%+3.7%43.1%
MRKMerck & Co., Inc.LTM Jun 2026$38.99B USD+46.3%-0.5%58.7%
AZNAstraZeneca PLCLTM Sep 2026$35.08B USD-0.0%+6.8%56.4%
PFEPfizer Inc.LTM Jun 2026$29.59B USD+0.7%+0.5%46.5%
SNYSanofiLTM Jun 2026€28.48B EUR+24.0%+9.1%58.2%
ABBVAbbVie Inc.LTM Sep 2026$26.88B USD-17.4%+0.5%40.7%
LLYEli Lilly and CompanyLTM Jun 2026$26.83B USD+24.4%+22.6%33.7%
GILDGilead Sciences, Inc.LTM Jun 2026$25.73B USD+76.1%-7.0%84.5%
NVSNovartis AGLTM Jun 2026$24.42B USD-3.8%+0.2%43.9%
AMGNAmgen Inc.LTM Jun 2026$15.05B USD+5.1%+14.0%39.5%
Peer median (excluding MRK) —+5.1%+3.7%43.9%

Competitors are the stored peer set for MRK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue48.7B59.28B60.12B64.17B64.93B
Cost of Revenue13.63B17.41B16.13B15.19B18.2B
Gross Profit35.08B41.87B43.99B48.98B46.73B
Gross Margin72.0%70.6%73.2%76.3%72.0%
Research & Development12.25B13.55B30.53B17.94B12.51B
Selling, General & Admin9.4B9.67B9.88B10.1B10.73B
Operating Expenses21.88B23.59B41.04B28.75B23.25B
Depreciation & Amortization3.21B3.91B3.87B4.5B5.84B
EBITDA17.9B21.32B6.91B25.71B28.26B
EBITDA Margin36.8%36.0%11.5%40.1%43.5%
Operating Income13.2B18.28B2.95B20.22B23.49B
Operating Margin27.1%30.8%4.9%31.5%36.2%
Interest Income36M157M365M415M343M
Interest Expense806M962M1.15B1.27B1.36B
Other Income / Expenses680M(1.84B)(1.07B)(285M)(2.42B)
Income Before Tax13.88B16.44B1.89B19.94B21.07B
Pre-Tax Margin28.5%27.7%3.1%31.1%32.4%
Income Tax Expense1.52B1.92B1.51B2.8B2.8B
Net Income13.05B14.52B365M17.12B18.25B
Net Margin26.8%24.5%0.6%26.7%28.1%
EPS (Basic)5.165.730.146.767.30
EPS (Diluted)5.145.710.146.747.28
Weighted Avg Shares2.53B2.53B2.55B2.53B2.5B
Weighted Avg Shares (Diluted)2.54B2.54B2.55B2.54B2.51B

Merck & Co., Inc.

NYSE:MRK

Intrinsic Alpha fair value

Locked

Current Price

$137.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.